Although the desired therapeutic outcome was not reached, pelareorep was found to induce cytopathic effects in those cells carrying KRAS mutations, which was meaningful and deserved to be highlighted since 70% to 90% of PCA cases have KRAS mutations through predecessors [169,170]. This evidence concerns the gene KRAS and posterior cortical atrophy.